FDMT (4D Molecular Therapeutics, Inc. Common Stock) Stock Analysis - News
4D Molecular Therapeutics, Inc. Common Stock (FDMT) is a publicly traded Healthcare sector company. As of May 21, 2026, FDMT trades at $8.49 with a market cap of $437.29M and a P/E ratio of -3.28. FDMT moved +0.89% today. Year to date, FDMT is +16.03%; over the trailing twelve months it is +120.00%. Its 52-week range spans $2.24 to $12.34. Analyst consensus is strong buy with an average price target of $29.00. Rallies surfaces FDMT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in FDMT news today?
4D Molecular Therapeutics Reports $458M Cash, Completes 523-Patient Phase 3 Enrollment: 4D Molecular Therapeutics ended Q1 2026 with $458 million cash, $3.0 million collaboration revenue, $65.0 million in R&D expenses and a $68.8 million net loss. The 523-patient 4FRONT-1 Phase 3 trial completed enrollment in March 2026, topline data due H1 2027 and 4FRONT-2 enrollment expected by H2 2026.
4D Molecular Therapeutics Reports $458M Cash, Completes 523-Patient Phase 3 Enrollment: 4D Molecular Therapeutics ended Q1 2026 with $458 million cash, $3.0 million collaboration revenue, $65.0 million in R&D expenses and a $68.8 million net loss. The 523-patient 4FRONT-1 Phase 3 trial completed enrollment in March 2026, topline data due H1 2027 and 4FRONT-2 enrollment expected by H2 2026.
Does Rallies summarize FDMT news?
Yes. Rallies summarizes FDMT news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is FDMT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for FDMT. It does not provide personalized investment advice.
